Navigation Links
M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients
Date:10/26/2007

may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release regarding procedure growth and market acceptance, clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward- looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products; need for additional long-term clinical data; the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the fiscal year ended June 30, 2007 and may be updated from time to time by our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward- looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
2. M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data at the AACR Annual Meeting
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Protox Announces Positive Clinical Data from Prostate Cancer Study
8. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
9. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
10. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
11. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... NOTTINGHAM, United Kingdom , Oct. 30, 2014 /PRNewswire/ ... Inc., (Nasdaq: CBRX ) and ... assist drug developers with improved efficiency during clinical development ... San Diego next week. This ... enabling technologies platform, which it launched earlier this month. ...
(Date:10/30/2014)... , Oct. 30, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... quarter 2014 financial results will be released on Thursday, ... a conference call and live webcast at 1:30 p.m. ...
(Date:10/30/2014)...   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced financial results for the third ... important corporate, commercial, regulatory and clinical development updates ... very pleased with the continued momentum and strong ... portfolio this quarter, especially the XIAFLEX franchise, which ...
Breaking Medicine Technology:Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22
... and Progressive Form of Inflammatory Spinal Arthritis Receiving Monthly Golimumab ... ... BOSTON, Nov. 7 More than half of patients receiving,monthly ... experienced significant and sustained improvements in the signs and,symptoms of active ...
... of Trial Volunteers Must Remain Paramount Concern, SEATTLE, ... the following statement today from Executive,Director Mitchell Warren in ... AIDS vaccine study by Merck & Co., the US ... HIV Vaccine Trials Network,(HVTN) at a public forum at ...
Cached Medicine Technology:New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 2New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 3New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 4New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 5New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 6New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 7AIDS Vaccine Advocacy Coalition Calls for AIDS Vaccine Field to Work Together to Analyze STEP Study Data and Determine Best Course to Move Forward 2AIDS Vaccine Advocacy Coalition Calls for AIDS Vaccine Field to Work Together to Analyze STEP Study Data and Determine Best Course to Move Forward 3
(Date:10/30/2014)... WHAT: , A mathematical model developed by NIH grantees ... daily to prevent HIV infection via vaginal sex, whereas ... HIV infection via anal sex. This finding helps explain ... or PrEP, in women failed to show efficacy. Participants ... trials of Truvada and tenofovir (another antiretroviral) for HIV ...
(Date:10/30/2014)... San Diego, Calif. (PRWEB) October 30, 2014 ... no longer mutually exclusive concepts in the medical-grade ... focusing on the development of uniquely potent topical ... Skin Health System ( http://www.RefinitySkinScience.com ) with patented ... highest available glycolic acid concentrations (50% and 70%) ...
(Date:10/30/2014)... By Steven Reinberg ... -- Giving hormone therapy to men with prostate cancer who ... dying from a heart-related cause, a new study suggests. , , ... It,s used in prostate cancer to reduce levels of male ... the study. And, in the current research, this hormone therapy ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Horse ... therapeutic horseback riding to special needs individuals in the ... on Saturday, November 15 from 10-2:00 p.m. at Bailey's ... is open to the public and is designed to ... , Admission to the HSS Round-Up is free. Ticket ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 The annual ... (NAMS) came to a close on Saturday, October 18th, ... the Society’s inception in 1989. NAMS is North America’s ... quality of life of all women during midlife and ... With over 2,000 physicians and thought leaders from fields ...
Breaking Medicine News(10 mins):Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3
... at Rice University have discovered that intense pressure -- ... half-mile beneath the ocean,s surface -- stimulates cartilage cells ... properties of natural cartilage. The new method, which requires ... of arthritis sufferers. , "This tissue-engineering method holds promise ...
... honoured with a Commendation in this year,s Premier,s Award ... Fellow and was previously a PhD student in WEHI,s ... Priscilla with the Commendation at a ceremony at Government ... on two key aspects of cancer biology. First, identifying ...
... once-a-week participation was associated with improved results , , WEDNESDAY, ... Anonymous offer benefits to adolescents, even if they eventually ... teens enrolled at two treatment centers in California. ... from four to six weeks at the centers, which ...
... societal, and health carerelated issues contribute to disparities in ... to two articles appearing in the July 2008 issue ... The articles indicate that immediate and substantial efforts on ... health care for affected Americans. Such concerted efforts can ...
... Provide Alaska Rural Telecommunication Services for Next ... ... GNCMA ),announced today that it successfully transitioned all of its rural,telecommunication ... Internet, distance education and,telehealth services throughout rural Alaska for the next 14 ...
... from Thomson Reuters to Analyze Promising Drugs Changing Clinical Phase, ... Generics ... ... leading source of intelligent information for businesses and,professionals, has announced the ...
Cached Medicine News:Health News:Cartilage regeneration '20,000 Leagues Under the Sea' 2Health News:Cartilage regeneration '20,000 Leagues Under the Sea' 3Health News:Insights into cancer earn Premier's Award Commendation 2Health News:Alcohol, Drug Counseling Benefits Teens, Too 2Health News:Racial disparities in the outcomes of patients with chronic kidney disease abound 2Health News:Racial disparities in the outcomes of patients with chronic kidney disease abound 3Health News:GCI Successfully Transitions All Traffic to Galaxy 18 Satellite 2Health News:The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline 2Health News:The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline 3
... rotary retracting, self-lubricating design and has a heavy ... construction makes it accurate and incredibly reliable. ,The ... lateral motion is controlled and allows no slop ... lesser designs which can result in 'chatter' and ...
... The new SureCut M3500 Radial Microtome has ... is marvelous, and a range of functions and ... users. Based on years of experience and ... innovative design the SureCut M3500 Microtome will be ...
This is an economical (portable) microtome designed for fast and accurate sectioning. The specimen rise is automatic and accurate with each handle movement. Section thickness from 5 to 40 microns. ...
Honing compound for knife sharpening, 6 grams net...
Medicine Products: